Chronic activation of B-cell receptor (BCR) signaling via Bruton tyrosine kinase (BTK) is
largely considered to be one of the primary mechanisms driving disease progression in B …

The approval of BTK and PI3K inhibitors (ibrutinib, idelalisib) represents a revolution in the
therapy of B cell malignancies such as chronic lymphocytic leukemia (CLL), mantle-cell …

IκBζ (encoded by NFKBIZ) is the most recently identified IkappaB family protein. As an
atypical member of the IkappaB protein family, NFKBIZ has been the focus of recent studies …

A large amount of circumstantial evidence has accumulated suggesting that Toll-like
receptor (TLR) signals are involved in driving chronic lymphocytic leukemia (CLL) cell …

Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in the western
world. Despite the positive clinical effects of new targeted therapies, CLL still remains an …

The MYD88 gene has a physiological role in the innate immune system. Somatic mutations
in MYD88, including the most common L265P, have been associated with the development …

Bruton's tyrosine kinase inhibitors (BTKi) have revolutionized the treatment of B‐cell
lymphoma (BCL). These drugs interfere with the mechanisms underlying malignant B‐cell …

Chronic lymphocytic leukemia (CLL), a highly heterogeneous B-cell malignancy, is
characterized by tumor microenvironment disorder and T-cell immune dysfunction, which …

Prostate cancer (PCa) is the second most common malignancy and is the fifth leading cause
of cancer mortality among men globally. Docetaxel‐based therapy remains the first‐line …

Chronic lymphocytic leukemia (CLL) is a prototypic neoplasia in which malignant cells
strongly depend on microenvironmental stimulations in the lymphoid tissues where they …